Ipamorelin is the growth-hormone peptide people reach for when they want a “clean” one. It nudges your own pituitary to release growth hormone without the hunger and hormone spikes of the older peptides in its family. It is popular, it is paired with CJC-1295 constantly, and it is also unproven for the reasons people actually use it. Here is the honest picture.
Thin where it counts. There is one solid short-term human study showing ipamorelin does release growth hormone, and there is a failed drug trial for a gut condition. What does not exist is any long-term human trial for the things people take it for: muscle, fat loss, recovery, or anti-aging. Those claims rest on growth-hormone physiology and personal reports, not on outcomes trials. Lead with that.
Ipamorelin is a synthetic five-amino-acid peptide. It is a growth-hormone secretagogue, which means it makes your body release its own growth hormone rather than supplying growth hormone from outside. Specifically it is a ghrelin mimetic, copying the “hunger hormone” ghrelin at one receptor. Its claim to fame is selectivity, which we will get to.
It was first described in 1998 by researchers at Novo Nordisk, in a paper literally titled “Ipamorelin, the first selective growth hormone secretagogue.” Novo never brought it to market. Later, another company tested it for postoperative ileus, the temporary gut paralysis that can follow abdominal surgery. That program failed (more below). It was never approved for anything.
Ipamorelin activates the growth-hormone-secretagogue receptor, the same one ghrelin uses, on the pituitary. That triggers a discrete pulse of growth hormone, peaking around 40 minutes after a dose and then fading. It amplifies a natural-style pulse rather than flooding the system.
The selectivity is the real story. Older peptides in this family, GHRP-6 and GHRP-2, also release growth hormone, but they push up cortisol, prolactin, and appetite along with it. Ipamorelin releases growth hormone with very little effect on cortisol, prolactin, or ACTH, even at doses far above what is needed. That cleaner profile is the whole reason people prefer it. It is also why it pairs so well with a GHRH peptide like CJC-1295, since the two hit different receptors and add up.
That is the entire human record. Notice what is missing: no long-term trials for body composition or anti-aging, the uses it is actually sold for.
The community uses it for lean mass, fat loss, sleep quality, recovery, skin, and general anti-aging, almost always stacked with a GHRH peptide. These are reasonable ideas based on what growth hormone does, but they are extrapolation and anecdote, not proof.
Reported effects are usually mild and short-term: injection-site reactions, headache, flushing, some water retention, and a bit of appetite. Because it works through growth hormone, the theoretical dose-dependent concerns are the classic growth-hormone ones, fluid retention, joint aches, carpal-tunnel-type symptoms, and effects on blood sugar and insulin.
The most important boundary is cancer risk. Anything that raises growth hormone and IGF-1 could in theory feed cell growth, so growth-hormone secretagogues are considered off-limits for anyone with active or recent cancer without an oncologist’s oversight. There is no long-term human safety data, and gray-market purity is a real, separate risk.
Reporting, not a recommendation. There is no approved human dose for the way people use it. Community sources describe subcutaneous injections in the low-hundreds-of-micrograms range per dose, often on an empty stomach and at bedtime to line up with the body’s natural nighttime growth-hormone pulse, and frequently paired one-to-one with CJC-1295. It comes as a powder that has to be reconstituted. We do not give mixing or injection steps. The only rigorously studied human dosing was intravenous, in the studies above, which is not how the community uses it.
Not FDA-approved for any use, and its compounding status is a genuine mess worth stating carefully. The FDA placed ipamorelin in “Category 2” in 2023, which flagged it as not usable in compounding pending review. It was reviewed at an FDA advisory meeting in October 2024, and no final rule has been issued. Importantly, ipamorelin was not in the July 2026 batch of peptides that got favorable advisory votes (that batch was BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP). So it sits in limbo, reviewed but undecided, and it is not legally available through compounding in the meantime. It is also banned in sport by WADA.
Almost always CJC-1295. The logic is that CJC-1295, a GHRH peptide, primes the pituitary while ipamorelin triggers the release pulse, and the two together produce more growth hormone than either alone. The two forms of CJC-1295, with DAC and without, change how that pairing is timed. See the CJC-1295 deep dive for that distinction.
Is ipamorelin the same as HGH? No. HGH is growth hormone itself. Ipamorelin prompts your own pituitary to release growth hormone in a pulse.
Is it FDA-approved? No, not for any use, and it is not currently available through legal compounding.
How is it different from GHRP-6 and GHRP-2? All three release growth hormone, but ipamorelin is far more selective, with much less cortisol, prolactin, and hunger.
Does it build muscle or reverse aging? There are no long-term human trials showing that. The popularity rests on growth-hormone physiology and anecdote.
Why is it stacked with CJC-1295? They hit two different receptors on the same pituitary cells and produce more growth hormone together.
Who should avoid it? Anyone with active or recent cancer, given the growth-hormone and IGF-1 effect, and anyone with blood-sugar concerns should be cautious.
Is it banned in sport? Yes, WADA-prohibited at all times, and detectable.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.